Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429803 | 0.86 | AKR1C3 (0.46) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL1125008 | 0.83 | CYP4F2 (0.45) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL7625059 | 0.83 | FAAH (0.46) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL13884372 | 0.83 | EPHX1 (0.45) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL31375120 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL3281060 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL2944919 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL12315605 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL8626625 | 0.82 | TSHR (0.40) | PTGS2LMNATSHR | |
| SCHEMBL3279844 | 0.82 | KMT2A (0.47) | PTGS2LMNAALOX5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440274-A | A kind of synthetic method of high-purity nonsteroidal anti-inflammatory drug loxoprofen sodium | 大桐制药（中国）有限责任公司 | 2018-08-24 | — | — | CN | disclosed |
| CN-104710309-A | Synthetic methods of loxoprofen sodium and intermediate thereof | ZHEJIANG APELOA PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2015-06-17 | — | — | CN | disclosed |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | disclosed |
| US-6706892-B1 | ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS | CONJUCHEM, INC. (CA) | 2004-03-16 | — | — | US | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
| US-4161538-A | 4-(2-OXO- OR HYDROXIMINO-CYCLOALKAN-1-YLMETHYL)-PHENYLACETIC ACID, ANTIINFLAMMATORY AGENTS | SANKYO COMPANY LIMITED (JP) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | OGFR, HDGF, SERPINA6 | PTGS2 345/4885PTGS1 28/4885CXCR1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.